Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa

Biological Psychiatry

Volumn 58, Issue 4, 2005, Pages 337-343

  Eltayb, Amani ^a   Wadenberg, Marie Louise G ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Augmentation therapy; Cognitive dysfunction; Cortical dopamine; L dopa; Rat; Schizophrenia

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; LEVODOPA; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCORING SYSTEM;

ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BENSERAZIDE; CATALEPSY; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; LEVODOPA; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RACLOPRIDE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 23644438216     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.03.038     Document Type: Article

References (65)

1. S. Ahlenius, V. Hillegaart Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs A comparison between the effects produced by pre- and postsynaptic inhibition of dopaminergic neurotransmission Pharmacol Biochem Behav 24 1986 1409 1415
2. M. Akil, J.N. Pierri, R.E. Whitehead, C.L. Edgar, C. Mohila, A.R. Sampson, D.A. Lewis Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects Am J Psychiatry 156 1999 1580 1589
3. M. Alpert, A.J. Friedhoff An un-dopamine hypothesis of schizophrenia Schizophr Bull 6 1980 387 390
4. B. Angrist, S. Gershon The phenomenology of experimentally induced amphetamine psychosis Preliminary observations Biol Psychiatry 2 1970 95 107
5. B. Angrist, E. Peselow, M. Rubenstein, J. Corwin, J. Rotrosen Partial improvement in negative schizophrenic symptoms after amphetamine Psychopharmacology 78 1982 128 130
6. B. Angrist, G. Sathananthan, S. Gershon Behavioral effects of L-dopa in schizophrenic patients Psychopharmacologia 31 1973 1 12
7. J. Arnt Pharmacological specificity of conditioned avoidance response inhibition in rats Inhibition by neuroleptics and correlation to dopamine receptor blockade Acta Pharmacol Toxicol 51 1982 321 329
8. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, A. de Bartolomeis Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations Evidence from a novel positron emission tomography method Proc Natl Acad Sci U S A 94 1997 2569 2574
9. A. Bruno, S.C. Bruno Effects of L-DOPA on pharmacological parkinsonism Acta Psychiatr Scand 42 1966 264 271
10. F.H. Buchanan, R.V. Parton, J.W. Warren, E.P. Baker Double blind trial of L-dopa in chronic schizophrenia Aust N Z J Psychiatry 9 1975 269 271
11. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 2002 381 389
12. M. Campbell, A.M. Small, P.J. Collins, E. Friedman, R. David, N. Genieser Levodopa and levoamphetamine A crossover study in young schizophrenic children Curr Ther Res Clin Exp 19 1976 70 86
13. R.J. Carey, M. Pinheiro-Carrera, H. Dai, C. Tomaz, J.P. Huston L-Dopa and psychosis Evidence for L-dopa-induced increases in prefrontal cortex dopamine and in serum corticosterone Biol Psychiatry 38 1995 669 676
14. W.T. Carpenter Jr The treatment of negative symptoms Pharmacological and methodological issues Br J Psychiatry Suppl 29 1996 17 22
15. S.A. Castner, G.V. Williams, P.S. Goldman-Rakic Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation Science 287 2000 2020 2022
16. L. Chen, C.R. Yang Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex J Neurophysiol 87 2002 2324 2336
17. J.R. Cooper, F.B. Bloom, R.H. Roth The Biochemical Basis of Neuropharmacology 2003 Oxford University Press New York
18. B. Ebert, U. Madsen, T.M. Lund, S.M. Lenz, P. Krogsgaard-Larsen Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4- isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA Neurochem Int 24 1994 507 515
19. M.F. Egan, T.E. Goldberg, B.S. Kolachana, J.H. Callicott, C.M. Mazzanti, R.E. Straub Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia Proc Natl Acad Sci U S A 98 2001 6917 6922
20. L. Farde, A.-L. Nordström, F.-A. Wiesel, S. Pauli, C. Halldin, G. Sedvall Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects Arch Gen Psychiatry 49 1992 538 544
21. J. Gerlach, K. Lühdorf The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs A double-blind cross-over trial with Madopar and placebo Psychopharmacologia 44 1975 105 110
22. T.E. Goldberg, L.B. Bigelow, D.R. Weinberger, D.G. Daniel, J.E. Kleinman Cognitive and behavioral effects of coadministration of dextro-amphetamine and haloperidol in schizophrenia Am J Psychiatry 148 1991 78 84
23. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 1996 321 330
24. P.J. Gresch, A.F. Sved, M.J. Zigmond, J.M. Finlay Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex J Neurochem 65 1995 111 116
25. P.D. Harvey, E. Howanitz, M. Parrella, L. White, M. Davidson, R.C. Mohs Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia A comparison across treatment sites Am J Psychiatry 155 1998 1080 1086
26. P. Hertel, G.G. Nomikos, M. Iurlo, T.H. Svensson Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade Science 286 1999 105 107
27. A. Imperato, L. Angelucci The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats Psychopharmacol Bull 25 1989 383 389
28. K. Inanaga, Y. Nakazawa, K. Inoue, H. Tachibana, M. Oshima, T. Kotorii Double-blind controlled study of L-dopa therapy in schizophrenia Folia Psychiatr Neurol Japon 29 1975 123 143
29. G.E. Jaskiw, A.P. Popli A meta-analysis of the response to chronic L-dopa in patients with schizophrenia Therapeutic and heuristic implications Psychopharmacology 171 2004 365 374
30. J.M. Kane, G. Honigfeld, J. Singer, H. Meltzer Clozapine in treatment-resistant schizophrenics Psychopharmacol Bull 24 1988 62 67
31. J.M. Kane, S.R. Marder, N.R. Schooler, W.C. Wirshing, D. Umbricht, R.W. Baker Clozapine and haloperidol in moderately refractory schizophrenia A 6-month randomized and double-blind comparison Arch Gen Psychiatry 58 2001 965 972
32. 2 occupancy, clinical response and side effects - a double blind PET study in first episode schizophrenia Am J Psychiatry 157 2000 514 520
33. S.R. Kay, L.A. Opler L-dopa in the treatment of negative schizophrenic symptoms A single subject experimental study Int J Psychiatr Med 15 1985 293 298
34. S. Kety Toward hypothesis for a biochemical component in the vulnerability to schizophrenia Semin Psychiatry 4 1972 233 238
35. U. Kischka, T. Kammer, S. Maier, M. Weisbrod, M. Thimm, M. Spitzer Dopaminergic modulation of semantic network activation Neuropsychologia 34 1996 1107 1113
36. H.L. Klawans, C. Goetz Jr, R. Westheimer Pathophysiology of schizophrenia in the striatum Dis Nervous Syst 33 1972 711 719
37. 2 receptors in the rat brain Biochem Pharmacol 34 1985 2251 2259
38. M. Laruelle, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. D'Souza, J. Erdos Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc Natl Acad Sci U S A 93 1996 9235 9240
39. M. Laruelle, A. Abi-Dargham Dopamine as the wind of the psychotic fire New evidence from brain imaging studies J Psychopharmacol 13 1999 358 371
40. C.C. Li Introduction to Experimental Statistics 1964 McGraw-Hill New York 207 226
41. Z. Li, J. Ichikawa, J. Dai, H.Y. Meltzer Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur J Pharmacol 493 2004 75 83
42. L.H. Lindström, O. Gefvert, G. Hagberg, T. Lundberg, M. Bergström, P. Hartvig, B. Långström Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET Biol Psychiatry 46 1999 681 688
43. D.A. Loeffler, P.A. LeWitt, P.L. Juneau, D.M. Camp, L.A. Arnold, K. Hyland Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation Brain Res Bull 47 1998 663 667
44. H.Y. Meltzer Treatment of the neuroleptic-nonresponsive schizophrenic patient Schizophr Bull 18 1992 515 542
45. H.Y. Meltzer, S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr Bull 25 1999 233 255
46. B. Moghaddam, B.S. Bunney Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat An in vivo microdialysis study J Neurochem 54 1990 1755 1760
47. I. Ninan, R.Y. Wang Modulation of the ability of clozapine to facilitate NMDA-and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine Pharmacological evidence Eur J Neurosci 17 2003 1306 1312
48. G.G. Nomikos, M. Iurlo, J.L. Andersson, K. Kimura, T.H. Svensson Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex Psychopharmacology 115 1994 147 156
49. J. Opacka-Juffry, S. Ashworth, R.G. Ahier, S.P. Hume Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET J Neural Transm 105 1998 349 364
50. G. Paxinos, C. Watson The Rat Brain in Stereotaxic Coordinates 2nd ed. 1986 Academic Press New York
51. B. Schilström, G.G. Nomikos, M. Nisell, P. Hertel, T.H. Svensson N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens Neuroscience 82 1998 781 789
52. P. Seeman Dopamine receptor sequences Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 Neuropsychopharmacology 7 1992 261 284
53. S. Siegel, N.J. Castellan Jr Nonparametric Statistics for the Behavioral Sciences 1988 McGraw-Hill New York
54. T.H. Svensson Dysfunctional brain dopamine systems induced by psychotomimetic NMDA receptor antagonists and the effects of antipsychotic drugs Brain Res Brain Res Rev 31 2000 320 329
55. T.H. Svensson Preclinical effects of conventional and atypical antipsychotic drugs Defining the mechanisms of action Clin Neurosci Res 3 2003 34 46
56. C.A. Tamminga, A. Carlsson Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis Curr Drug Target CNS Neurol Disord 1 2002 141 147
57. S. Tucci, R. Fernandez, T. Baptista, E. Murzi, L. Hernandez Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats Brain Res Bull 35 1994 125 133
58. D.P. Van Kammen, J.J. Boronow Dextro-amphetamine diminishes negative symptoms in schizophrenia Int Clin Psychopharmacol 3 1988 111 121
59. M.-L. Wadenberg, P.B. Hicks The conditioned avoidance response test re-evaluated Is it a sensitive test also for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23 1999 851 862
60. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats Psychopharmacology 150 2000 422 429
61. M.-L. Wadenberg, A. Soliman, S.C. VanderSpek, S. Kapur Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641
62. D.R. Weinberger, M.F. Egan, A. Bertolino, J.H. Callicott, V.S. Mattay, B.K. Lipska Prefrontal neurons and the genetics of schizophrenia Biol Psychiatry 50 2001 825 844
63. B.H. Westerink, Y. Kawahara, P. De Boer, C. Geels, J.B. De Vries, H.V. Wikstrom Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum Eur J Pharmacol 412 2001 127 138
64. B.K. Yamamoto, S. Novotney Regulation of extracellular dopamine by the norepinephrine transporter J Neurochem 71 1998 274 280
65. J.A. Yaryura-Tobias, B. Diamond, S. Merlis The action of L-dopa on schizophrenic patients (a preliminary report) Curr Ther Res Clin Exp 12 1970 528 531